US20020156034A1 - CXCR4 antagonist treatment of hematopoietic cells - Google Patents

CXCR4 antagonist treatment of hematopoietic cells Download PDF

Info

Publication number
US20020156034A1
US20020156034A1 US09/852,424 US85242401A US2002156034A1 US 20020156034 A1 US20020156034 A1 US 20020156034A1 US 85242401 A US85242401 A US 85242401A US 2002156034 A1 US2002156034 A1 US 2002156034A1
Authority
US
United States
Prior art keywords
lkwiqeylekaln
seq
cells
kgvsl
kgvs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/852,424
Other languages
English (en)
Inventor
Christopher Tudan
Ahmed Merzouk
Lakhdar Arab
Geeta Saxena
Connie Eaves
Johanne Cashman
Ian Clark-Lewis
Hassan Salari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Chemokine Therapeutics Corp USA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/852,424 priority Critical patent/US20020156034A1/en
Application filed by Individual filed Critical Individual
Assigned to UNIVERSITY OF BRITISH COLUMBIA, THE reassignment UNIVERSITY OF BRITISH COLUMBIA, THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CASHMAN, JOHANNE, CLARK-LEWIS, IAN, EAVES, CONNIE J.
Assigned to CHEMOKINE THERAPEUTICS CORPORATION reassignment CHEMOKINE THERAPEUTICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARAB, LAKHDAR, MERZOUK, AHMED, TUDAN, CHRISTOPHER R., SALARI, HASSAN, SAXENA, GEETA
Publication of US20020156034A1 publication Critical patent/US20020156034A1/en
Priority to US10/945,674 priority patent/US7435718B2/en
Priority to US11/649,928 priority patent/US20070160574A1/en
Priority to US11/752,725 priority patent/US20080318855A1/en
Priority to US12/189,764 priority patent/US20090192082A1/en
Priority to US12/646,915 priority patent/US20110230422A1/en
Priority to US12/646,921 priority patent/US20110118193A1/en
Priority to US12/883,142 priority patent/US20110002885A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4

Definitions

  • the invention relates to therapeutic uses of chemokine receptor antagonists, including peptide antagonists of CXC chemokine receptor 4 (CXCR4) for use in the treatment of hematopoietic cells in vitro and in vivo.
  • CXCR4 CXC chemokine receptor 4
  • the invention relates to novel CXCR4 antagonists which may be used in the treatment of hematopoietic cells.
  • Cytokines are soluble proteins secreted by a variety of cells including monocytes or lymphocytes that regulate immune responses. Chemokines are a superfamily of chemoattractant proteins. Chemokines regulate a variety of biological responses and they promote the recruitment of multiple lineages of leukocytes and lymphocytes to a body organ tissue. Chemokines may be classified into two families according to the relative position of the first two cysteine residues in the protein. In one family, the first two cysteines are separated by one amino acid residue, the CXC chemokines, and in the other family the first two cysteines are adjacent, the CC chemokines.
  • CXC chemokines Two minor subgroups contain only one of the two cysteines (C) or have three amino acids between the cysteines (CX 3 C).
  • CXC chemokines are clustered on chromosome 4 (with the exception of SDF-1 gene, which has been localized to chromosome 10) and those of the CC chemokines on chromosome 17.
  • CXC chemokine receptor 4 CXCR4
  • HIV-1 entry cofactor Functional cDNA cloning of a seven-transmembrane G protein-coupled receptor, Science 272, 872-877.
  • CXCR4 is widely expressed on cells of hemopoietic origin, and is a major co-receptor with CD4 + for human immunodeficiency virus 1 (HIV-1) (Feng, Y., Broeder, C.C., Kennedy, P. E., and Berger, E. A. (1996) HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane G protein-coupled receptor, Science 272, 872-877).
  • HIV-1 entry cofactor Functional cDNA cloning of a seven-transmembrane G protein-coupled receptor, Science 272, 872-877.
  • Chemokines are thought to mediate their effect by binding to seven-transmembrane G protein-coupled receptors, and to attract leukocyte subsets to sites of inflammation (Baglionini et al. (1998) Nature 392: 565-568). Many of the chemokines have been shown to be constitutively expressed in lymphoid tissues, indicating that they may have a homeostatic function in regulating lymphocyte trafficking between and within lymphoid organs (Kim and Broxmeyer (1999) J. Leuk. Biol. 56: 6-15).
  • Stromal cell derived factor one is a member of the CXC family of chemokines that has been found to be constitutively secreted from the bone marrow stroma (Tashiro, (1993) Science 261, 600-602). The human and mouse SDF-1 predicted protein sequences are approximately 92% identical.
  • Stromal cell derived factor-1a (SDF-1a) and stromal cell derived factor-1 ⁇ (SDF-1 ⁇ ) are closely related (together referred to herein as SDF-1).
  • the native amino acid sequences of SDF-1 ⁇ and SDF-1 ⁇ are known, as are the genomic sequences encoding these proteins (see U.S. Pat. No. 5,563,048 issued Oct. 8, 1996, and U.S. Pat. No.
  • Biological effects of SDF-1 may be mediated by the chemokine receptor CXCR4 (also known as fusin or LESTR), which is expressed on mononuclear leukocytes including hematopoietic stem cells.
  • CXCR4 also known as fusin or LESTR
  • SDF-1 is thought to be the natural ligand for CXCR4, and CXCR4 is thought to be the natural receptor for SDF-1 (Nagasawza et al. (1997) Proc. Natl. Acad. Sci. USA 93:726-732).
  • Genetic elimination of SDF-1 is associated with parinatal lethality, including abnormalities in cardiac development, B-cell lymphopoiesis, and bone marrow myelopoiesis (Nagasawa et al. (1996) Nature 382:635-637).
  • SDF-1 is functionally distinct from other chemokines in that it is reported to have a fundamental role in the trafficking, export and homing of bone marrow progenitor cells (Aiuti, A., Webb, I. J., Bleul, C., Springer, T., and Guierrez-Ramos, J. C., (1996) J. Exp. Med. 185, 111-120 and Nagasawa, T., Hirota, S., Tachibana, K., Takakura N., Nishikawa, S.
  • SDF-1 is also structurally distinct in that it has only about 22% amino acid sequence identity with other CXC chemokines (Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A., and Springer, T. A., (1996) J. Exp. Med. 184, 1101-1109).
  • SDF-1 appears to be produced constitutively by several cell types, and particularly high levels are found in bone-marrow stromal cells (Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H. Shinohara, T., and Honjo, T., (1995) Genomics, 28, 495-500 and Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A., and Springer, T. A., (1996) J. Exp. Med. 184, 1101-1109).
  • a basic physiological role for SDF-1 is implied by the high level of conservation of the SDF-1 sequence between species.
  • SDF-1 stimulates chemotaxis of a wide range of cells including monocytes and bone marrow derived progenitor cells (Aiuti, A., Webb, I. J., Bleul, C., Springer, T., and Guierrez-Ramos, J. C., (1996) J. Exp. Med. 185, 111-120 and Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A., and Springer, T. A., (1996) J. Exp. Med. 184, 1101-1109). SDF-1 also stimulates a high percentage of resting and activated T-lymphocytes (Bleul, C.
  • a variety of diseases require treatment with agents that are preferentially cytotoxic to dividing cells.
  • Cancer cells may be targeted with cytotoxic doses of radiation or chemotherapeutic agents.
  • a significant side-effect of this approach to cancer therapy is the pathological impact of such treatments on rapidly dividing normal cells.
  • These normal cells may for example include hair follicles, mucosal cells and the hematopoietic cells, such as primitive bone marrow progenitor cells and stem cells.
  • the indiscriminate destruction of hematopoietic stem, progenitor or precursor cells can lead to a reduction in normal mature blood cell counts, such as leukocytes, lymphocytes and red blood cells.
  • neutrophils neutrophils
  • platelets thrombocytopenia
  • a decrease in leukocyte count, with concomitant loss of immune system function, may increase a patient's risk of opportunistic infection.
  • Neutropaenia resulting from chemotherapy may for example occur within two or three days of cytotoxic treatments, and may leave the patient vulnerable to infection for up to 2 weeks until the hematopoietic system has recovered sufficiently to regenerate neutrophil counts.
  • a reduced leukocyte count (leukopenia) and/or a platelet count (granulocytopenia) as a result of cancer therapy may become sufficiently serious that therapy must be interrupted to allow the white blood cell count to rebuild.
  • Hematopoietic cells that are uncommitted to a final differentiated cell type are identified herein as “progenitor” cells.
  • Hematopoietic progenitor cells possess the ability to differentiate into a final cell type directly or indirectly through a particular developmental lineage.
  • Undifferentiated, pluripotent progenitor cells that are not committed to any lineage are referred to herein as “stem cells.” All hematopoietic cells can in theory be derived from a single stem cell, which is also able to perpetuate the stem cell lineage as daughter cells become differentiated.
  • the isolation of populations of mammalian bone marrow cell populations which are enriched to a greater or lesser extent in pluripotent stem cells has been reported (see for example, C. Verfaillie et al., J. Exp. Med., 172, 509 (1990), incorporated herein by reference).
  • Bone marrow transplantation has been used in the treatment of a variety of hematological, autoimmune and malignant diseases.
  • ex vivo hematopoietic (bone marrow) cell culture may be used to expand the population of hematopoietic cells, particularly progenitor or stem cells, prior to reintroduction of such cells into a patient.
  • hematopoietic cells may be transformed in vitro prior to reintroduction of the transformed cells into the patient.
  • a selected nucliec acid such as a gene
  • a vector such as a viral vector
  • the vector transfected into a hematopoietic cell
  • the cell then may then be introduced into a patient.
  • Hematopoietic stem cells were initially identified as a prospective target for gene therapy (see e.g., Wilson, J. M., et al., Proc. Natl. Acad. Sci 85: 3014-3018 (1988)).
  • problems have been encountered in efficient hematopoietic stem cell transfection (see Miller, A.
  • hematopoietic stem cell transplantation therapy may be limited by several features.
  • the acquisition of enough stem cells for clinical use may require either a bone marrow harvest under general anesthesia or peripheral blood leukapheresis; both are expensive and carry a risk of morbidity.
  • Grafts may contain only a limited number of useful hematopoietic progenitors. Additionally, the kinetics of short-term stem cell engraftment may be such that for the first 1-3 weeks after infusion, these cells offer little hematopoietic support, and therefor the recipients may remain profoundly myelosuppressed during this time.
  • Hematopoietic stem cells are reportedly found in peripheral blood of healthy persons. Their numbers however, may be insufficient to permit collection of an adequate graft by standard leukapheresis (Kessionger, A. et al., Bone Marrow Transplant 6, 643-646 (1989)). Fortunately, a variety of methods have been discovered to increase the circulation of progenitor and stem cells by “mobilizing” them from the marrow into the peripheral blood. For autologous transplantation, hematopoietic stem/progenitor cells may be mobilized into the peripheral blood (Lane T. A.
  • Hematopoietic stem cell mobilization into peripheral blood has been used as a procedure following myelosuppressive chemotherapy regimens to mobilize hematopoietic stem and progenitor cells into the peripheral blood.
  • Suggested treatment regimens for mobilization may include cyclophosphamide alone, in single doses of 4-7 g/m2, or other agents such as Adriamycin (doxorubicin), carboplatin, Taxol (paclitaxel), etoposide, ifosfamide, daunorubicin, cytosine arabinosides 6-thioguanine, either alone or in combination (Richman, C. M. et al., Blood 47, 1031-1039 (1976); Stiff P. J.
  • HSC Hematopoietic stem cells collected from mobilized peripheral blood progenitor cells
  • PBPC peripheral blood progenitor cells
  • Purported advantages of PBPC transplantation include rapid and durable trilineage hematologic engraftment, improved tolerance of the harvesting procedure (without general anesthesia), and possibly diminished tumor contamination in the autologous setting (Lasky L. C. et al., Transfusion 21, 247-260 (1981); Moss T. J. et al, Blood 76,1879-1883)).
  • PBPC mobilization employing a combination of chemotherapy and followed by growth factor (GM-CSF or G-CSF) administration is more effective than either chemotherapy or growth factor alone (Siena S. et al., Blood 74, 1905-1914 (1989); Pettengel R. et al., Blood, 2239-2248 (1993); Haas R. et al., Bone Marrow Transplant 9, 459-465 (1992); Ho A. D. et al., Leukemia 7, 1738-1746 (1993)).
  • the combination reportedly results in a 50- to 75-fold increase in circulating CFU-GM and 10- to 50-fold increase in CD34+cells (Pettengel R.
  • tumour therapy dose intensification as a means of improving tumour response rates and perhaps patient survival
  • alternative therapies to either improve or replace current treatments to rescue the myeloablative effects of chemotherapy and/or radiation therapy has escalated, and is currently one of the major rate limiting factors for tumour therapy dose escalations.
  • Transplanted peripheral blood stem cells may provide a rapid and sustained hematopoietic recovery after the administration of high-dose chemotherapy or radiation therapy in patients with hematological malignancies and solid tumours.
  • PBSC transplantation has become the preferred source of stem cells for autologous transplantation because of the shorter time to engraftment and the lack of a need for surgical procedures such as are necessary for bone marrow harvesting (Demirer et al. (1996) Stem Cells 14:106-116; Pettengel et al., (1992) Blood 82:2239-2248).
  • G-CSF and GM-CSF are currently the most commonly used hematopoietic growth factors for PBSC mobilization, although the mobilized cellular profiles can differ significantly from patient to patient. Therefore, other agents are required for this clinical application.
  • lymphocyte depletion has also been recommended, where lymphocyte depletion is a form of purging autoreactive cells from the graft.
  • GVHD graft-versus-host disease
  • any concurrent therapy that may enhance the survival of the CFU-GEMM myeloid stem cells, or BFU-E, CFU-Meg (CFU-MK) and CFU-GM myelomonocytic stem cells may be beneficial in therapies for autoimmune diseases where hematopoietic stem cells could be compromised.
  • Depressed platelet count after PBPC collection may occur in healthy donors of allogeneic transplants.
  • the decrease in platelet counts during apheresis for autologous transplant recipient can reportedly be substantial, especially for those heavily pretreated patients mobilized with chemotherapy plus growth factor.
  • Platelet transfusion may be considered when the postapheresis count drops below 20.000/mm3, although the threshold should be individualized and depends on the status of the patient (inpatient vs. outpatient), the history of platelet recovery after chemotherapy, the amount of infused anticoagulant (hence the number of prior apheresis sessions within the same mobilization and collection series), and whether apheresis will be performed the next day.
  • the platelets may by infused fresh or cryopreserved for later infusion. (Schiffer C. A. et al., Ann N. Y. Acad. Sci. 411, 161-169 (1983)).
  • the platelet cryopreservation procedure has not been universally accepted. (Law P., Exp. Hematol. 10, 351-357 (1983)).
  • the PBPC product of patients with a low platelet count and who require transfusion typically does not contain enough platelet to warrant processing (Lane, unpublished observation (Lane T. A. Transfusion 36, 585-589 (1996)).
  • Retroviruses fill the need for stable and relatively efficient integration of engineered genetic elements into the chromosomes of target T cells.
  • Other viral vector systems currently available such as adenovirus or adenovirus-associated viral vectors, or transfection methods, such as lipofection, electroporation, calcium phosphate precipitation, or bioballistics, may lack similar efficiency for long-term expression of the transgenes in dividing HSC.
  • Some vectors may not enter the cells in sufficient numbers without cytotoxicity and/or may not integrate stability into the chromosomes with useful efficiency. In dividing cells, unintegrated DNA is generally diluted and lost.
  • Adenoviral vectors may also be highly immunogenic.
  • Retrovirus-mediated gene transfer into murine hematopoietic stem cells and reconstitution of syngeneic mice has demonstrated persistence and functioning of the transgenes over extended period of time (Kume et al. (1999) 69:227-233). Terminally differentiated cells are relatively short-lived, except for memory B and T lymphocytes, and a large number of blood cells are replaced daily. Therefore, when long-term functional correction of blood cells by gene transfer is required, the target cells may be hematopoietic stem cells (Kume et al. (1999) 69:227-233).
  • Compounds that can maintain the survival and/or self-renewal (for example enhanced number of cells in S-phase of the cell cycle) of the progenitor stem cells may therefore increase the efficiency of the gene transfer in that a greater population of hematopoietic stems cells is available.
  • a number of proteins have been identified and may be utilized clinically as inhibitors of hematopoietic progenitor cell development and hematopoietic cell proliferation or multiplication. These include recombinant-methionyl human G-CSF (Neupogen®, Filgastim; Amgen), GM-CSF (Leukine®, Sargramostim; Immunex), erythropoietin (rhEPO, Epogen®; Amgen), thrombopoietin (rhTPO; Genentech), interleukin-11 (rhIL-11, Neumega®; American Home Products), Flt3 ligand (Mobista; Immunex), multilineage hematopoietic factor (MARstemTM; Maret Pharm.), myelopoietin (Leridistem; Searle), IL-3, myeloid progenitor inhibitory factor-1 (Mirostipen; Human Genome Sciences), stem cell factor (rhSCF, Stemgen®;
  • CXCR4 antagonists may be used to treat hematopoietic cells, for example to increase the rate of hematopoietic stem or progenitor cellular multiplication, self-renewal, expansion, proliferation, or peripheralization.
  • the invention relates to methods of promoting the rate of hematopoietic cell multiplication, which encompases processes that increase and/or maintain cellular multiplication, self-renewal, expansion, proliferation or peripheralization. This may for example be useful in some embodiments for in vitro hematopoietic cell cultures used in bone marrow transplantation, peripheral blood mobilization, or ex vivo expansion.
  • CXCR4 antagonists may also be used therapeutically to stimulate hematopoietic cell multiplication, self-renewal, expansion, proliferation or peripheralization in vivo, for example in some embodiments involving human diseases such as a cancer or an autoimmune disease.
  • the hematopoietic cells targeted by the methods of the invention may include hematopoietic progenitor or stem cells.
  • CXCR4 antagonists may be used to treat a variety of hematopoietic cells, and such cells may be isolated or may form only part of a treated cell population in vivo or in vitro.
  • Cells amenable to treatment with CXCR4 antagonists may for example include cells in the hematopoietic lineage, beginning with pluripotent stem cells, such as bone marrow stem or progenitor cells, lymphoid stem or progenitor cells, myeloid stem cells, CFU-GEMM cells (colony-forming-unit granulocyte, erythroid, macrophage, megakaryocye), B stem cells, T stem cells, DC stem cells, pre-B cells, prothymocytes, BFU-E cells (burst-forming unit—erythroid), BFU-MK cells (burst-forming unit—megakaryocytes), CFU-GM cells (colony-formng unit—granulocyte-macrophage), CFU-GM cells (colon
  • the invention provides methods of increasing the circulation of hematopoietic cells by mobilizing them from the marrow to the peripheral blood comprising administering an effective amount of a CXCR4 antagonist to hematopoietic cells of a patient undergoing autologous mobilization where hematopoietic stem/progenitor cells may be mobilized into the peripheral blood (1) during the rebound phase of the leukocytes and/or platelets after transient granulocytopenia and thrombocytopenia induced by myelosuppressive chemotherapy, (2) by hematopoietic growth factors, or (3) by a combination of both.
  • Such treatment may for example be carried out so as to be effective to mobilize the hematopoietic cells from a marrow locus (i.e. a location in the bone marrow) to a peripheral blood locus (i.e. a location in the peripheral blood).
  • a marrow locus i.e. a location in the bone marrow
  • a peripheral blood locus i.e. a location in the peripheral blood.
  • Such treatments may for example be undertaken in the context of or for the clinical procedure of leukapheresis or apheresis.
  • CXCR4 antagonists may be used in ex vivo stem cell expansion to supplement stem cell grafts with more mature precursors to shorten or potentially prevent hematopoietic cell depletion, including conditions such as pancytopenia, granulocytopenia, thrombocytopenia, anemia or a combination thereof; to increase the number of primitive progenitors to help ensure hematopoietic support for multiple cycles of high-dose therapy; to obtain sufficient number of stem cells from a single marrow aspirate or apheresis procedure, thus reducing the need for large-scale harvesting of marrow of multiple leukopheresis; to generate sufficient cells from a single cord-blood unit to allow reconstitution in an adult after high-dose chemotherapy; to purge stem cell products of contaminating tumour cells; to generate large volumes of immunologically active cells with antitumour activity to be used in immunotherapeutic regimens or to increase the pool of stem cells that could be targets for the delivery of gene therapy.
  • the invention provides methods to enrich CD34+ progenitor cells which are utilized in bone marrow (BM) and peripheral blood (PB) stem cell transplantation, wherein the hematopoietic stem cell transplantation (HSCT) protocols may for example be utilized for the purpose of treating the following diseases (from Ball, E. D., Lister, J., and Law, P.
  • Hematopoietic Stem Cell Therapy Chruchill Livingston (of Harcourt Inc.), New York (2000)): Aplastic Anemia; Acute Lymphoblastic Anemia.; Acute Myelogenous Leukemia; Myelodysplasia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Congenital Immunodeficiencies (such as Autoimmune Lymphoproliferative disease, Wiscott-Aldrich Syndrome, X-linked Lymphoproliferative disease, Chronic Granulamatous disease, Kostmann Neutropenia, Leukocyte Adhesion Deficiency); Metabolic Diseases (for instance those which have been HSCT indicated such as Hurler Syndrome (MPS I/II), Sly Syndrome (MPS VII), Chilhood onset cerebral X-adrenoleukodystrophy, Globard_cell Leukodystrophy).
  • Hurler Syndrome MPS I/II
  • Sly Syndrome MPS VII
  • peptide CXCR4 antagonists of the invention may comprise an N-terminal portion derived from SDF-1, covalently joined by a linker to a second N-terminal peptide, containing or now modifications to mimic N-terminal beta-turning, or C-terminal alpha-helices.
  • the SDF-1 antagonist may also exist as an N-terminal Dimer.
  • FIG. 1 shows the effects of CXCR4 receptor binding of SDF-1 peptide antagonists in an 125 1-SDF-1 binding competition assay.
  • Full length SDF-1 antagonist and the indicated analogs (competing ligands) were added to CEM cells in the presence of 4 nM 125 O-SDF-1.
  • CEM cells were assessed for 125 I-SDF-1 binding following 2 hr incubation. The results are expressed as percentage of the maximal specific binding that was determined without competing ligand.
  • FIG. 2 shows the effect of SDF-1 peptide antagonists (defined in Examples) on the cycling of human progenitors from fetal liver transplanted NOD/SCID mice.
  • the cycling status of mature and primitive colony forming cells (CFU-GM; colony forming unit-granulocyte-monocyte precursor, BFU-E; burst forming unit-erythroid precursor) in the suspension of CD34 + cells isolated from the marrow of transplanted NOD/SCID mice was determined by assessing the proportion of these progenitors that were inactivated (killed) by short term (20 min) or overnight (LTC-IC;Iong-term culture initiating cell) exposure of the cells to 20 ⁇ g/ml of high specific activity 3 H-thymidine.
  • FIG. 3 shows the effect of SDF-1 peptide antagonists (defined in Examples) on the engraftment of human cells in human fetal liver transplanted NOD/SCID mice.
  • SDF-1 peptide antagonists defined in Examples
  • the invention provides uses for CXCR4 antagonists derived from SDF-1 [P2G] in which glycine is substituted for proline at amino acid position 2.
  • SDF-1(1-67)[P2G], or SDF-1[P2G] (SEQ ID No. 1) is a potent CXCR4 receptor antagonist (Crump et al., (1997) EMBO J. 16(23): 6996-7007).
  • SDF-1 binds to CXCR4 primarily via its N-terminus, which appears flexible in the NMR studies of active N-terminal peptides of SDF-1 (Elisseeva et al., J.
  • beta-turn induction/‘locking’ Another mechanism of beta-turn induction/‘locking’ is the introduction of the Bicyclic Turned Dipetide (Btd), as a beta-turn mimetic (Ukon Nagai et al Tetrahedron (1993) 49(17) 3577-3592) in the sequence of the full length anatagonist as for proline and proline schimera.
  • Btd Bicyclic Turned Dipetide
  • two successive amino acid are replaced at once by the Btd molecule, which when inserted into the SDF-1 [P2G] antagonist are designated as SEQ ID No. 10-12.
  • a variety of small SDF-1 peptide analogues may also be used as CXCR4 antagonists, as disclosed in International Patent Publications WO 00/09152 (published 24 February 2000) and WO 99/47158 (published Sep. 23, 1999), each of which is incorporated herein by reference.
  • One such peptide may be a monomer having the following sequences; KGVSLSYRCPCRFFESH (SEQ ID No. 13); KGVSLSYRC (SEQ ID No. 14), or dimer of amino acids 1-9 (within SEQ ID No.
  • amino acid chains are joined by a disulphide bond between each of the cysteines at position 9 in each sequence (designated SDF-1 (1-9) 2 [P2G] with the following sequence: KGVSLSYRC-CRYSLSVPK (SEQ ID No. 15)).
  • SDF-1 (1-9) 2 [P2G] with the following sequence: KGVSLSYRC-CRYSLSVPK (SEQ ID No. 15)
  • Other An alternative peptides may for example be selected from the group consisting of peptides: KGVSLSYR-X-RYSLSVPK (SEQ ID No.
  • analogues based on the SEQ ID No. 16 are as follows, designated SEQ ID Nos. 50-61).
  • X may be an amino acid like lysine; ornithine or any other natural or unnatural amino acid serving as a linker between each of the arginines at position 8 in each sequence.
  • the CXCR4 antagonists for use in the invention may be substantially purified peptide fragments, modified peptide fragments, analogues or pharmacologically acceptable salts of either SDF-1 ⁇ or SDF-1 ⁇ .
  • SDF-1 derived peptide antagonists of CXCR4 may be identified by known physiological assays and a variety of synthetic techniques (such as disclosed in Crump et al., 1997, The EMBO Journal 16(23) 6996-7007; and Heveker et al., 1998, Current Biology 8(7): 369-376; each of which are incorporated herein by reference).
  • Such SDF-1 derived peptides may include homologs of native SDF-1, such as naturally occurring isoforms or genetic variants, or polypeptides having substantial sequence similarity to SDF-1, such as 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% sequence identity to at least a portion of the native SDF-1 sequence, the portion of native SDF-1 being any contiguous sequence of 10, 20, 30, 40, 50 or more amino acids, provided the peptides have CXCR4 antagonist activity.
  • chemically similar amino acids may be substituted for amino acids in the native SDF-1 sequence (to provide conservative amino acid substitutions).
  • peptides having an N-terminal LSY sequence motif within 10, or 7 amino acids of the N-terminus, and/or an N-terminal RFFESH (SEQ ID No. 62) sequence motif within 20 amino acids of the N-terminus may be used provided they have CXCR4 antagonistic activity.
  • One family of such peptide antagonist candidates has an LSY motif at amino acids 5-7.
  • Alternative peptides further include the RFFESH (SEQ ID No. 62) motif at amino acids 12-17.
  • the LSY motif is located at positions 3-5 of a peptide.
  • the invention also provides peptide dimers having two amino acid sequences, which may each have the foregoing sequence elements, attached by a disulfide bridge within 20, or preferably within 10, amino acids of the N terminus, linking cysteine residues or ⁇ -aminobutric acid residues.
  • the invention relates to novel CXCR4 antagonists derived from SDF-1[P2G] and their use to increase the rate of cellular multiplication and/or self-renweal of hematopoietic stem/progenitor cells.
  • the antagonist compounds of the invention comprise an N-terminal portion of SDF-1[P2G] covalently jointed by a linker to a second peptide.
  • the N-terminal portion may be any portion of the SDF-1 [P2G] N-terminus which binds to CXCR4.
  • the second peptide which does not include an N-terminal portion of SDF-1 [P2G], preferably enhances the antagonistic effect of the compound and may be a C-terminal fragment of SDF-1, for example any C-terminal fragment of any chemokine that known to improve the activity by binding to GAG's. (refer to Gabriele S. et al., Biochemistry (1999), 38: 12959-12968).
  • SDF-1 Antagonists include an acid or amide peptide analog having SDF-1 [P2G] N terminal amino acids 1-14 or 1-17 linked to C-terminal residues 55-67 by a four glycine linker: KGVSLSYRCPCRFF -GGGG- LKWJQEYLEKALN (SEQ ID No.63) KGVSLSYRCPCRFFESH -GGGG- LKWIQEYLEKALN (SEQ ID No.64)
  • the number of glycines linking the N-terminal and C-terminal amino acids may be varied, for example between 0 and 10, and may be 4, 3 or 2 in selected embodiments.
  • the size of the linker may be adapted to correspond approximately to the distance between C-terminal and N-terminal regions in the native folded SDF-1 structure.
  • a (CH 2 ) n linker may be used to join the N-terminal and C-terminal amino acids: KGVSLSYRCPCRFF -(CH 2 ) n - LKWIQEYLEKALN (SEQ ID No.65) KGVSLSYRCPCRFFESH -(CH 2 ) n - LKWIQEYLEKALN (SEQ ID No. 66)
  • the length of the linker may be adapted to correspond to the distance between the N- and C-terminal end of the full length SDF-1[P2G] polypeptide in its native form (where the amino acids replaced by the corresponding linker are present).
  • N-terminal LSYR residues which form a beta-turn may be modified, similarly as the full length SDF-1 [P2G] anatagonist, for example, by substituting leucine (L); serine (S); tyrosine (y) and arginine (R) with proline (P): KGVSPSYRCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No.67) KGVSLPYRCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No.68) KGVSLSPRCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No.69) KGVSLSYPCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No.70) KGVSPSYRCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No.
  • leucine (L), Seine (S), tyrosine (Y) or arginine (R) may be substituted with proline-amino acid chemira (P*) (similar to Seq ID No.
  • the peptidomimetics are of BTD (Bicyclo Turned Dipeptide) as described previously for the full length SDf-1 antagonist (SEQ ID No. 99-110): KGVSBtdYRCPCRFF -GGGG- LKWIQEYLEKALN (SEQ ID No. 99) KGVSLBtdRCPCRFF -GGGG- LKWIQEYLEKALN (SEQ ID No. 100) KGVSLSBtdCPCRFF -GGGG- LKWIQEYLEKALN (SEQ ID No. 101) KGVSBtdYRCPCRFFESH -GGGG- LKWIQEYLEKALN (SEQ ID No.
  • the SDF-1-derived CXCR4 antagonists of the invention may be linear or cyclized.
  • the antagonists may be cyclized at glutamic acid at position 24 with lysine at position 20 or 28 by removing the allylic group from both side chains of lysine and glutamic acid using the palladium-(0) technique (as described in Kates et al., (1993) Anal. Biochem. 212, 303-310): 1-Allyl removal: A solution of tetrakis(triphenylphosphine)palladium(0) (3 fold excess) dissolved in 5% Acetic acid; 2.5% N-methylmorpholine (NMM) in chloroform under argon.
  • NMM N-methylmorpholine
  • the solution is added to the support-bound peptide previously removed from the column in a reaction vial containing a small magnetic bar for gentle stirring.
  • the mixture is flushed with argon, sealed and stirred at room temperature for 6 hours.
  • the support-bound peptide is transferred to a filter funnel, washed with a solution made of 0.5% sodium diethyldithiocarbamate in dichloromethane (DMF) and then dichloromethane.
  • 0.2-Lactam formation is mediated by internal amide bond formation between the lysine and glutamic acid. Cyclisation is carried out manually in a peptide synthesis vial at room temperature overnight with gentle agitation.
  • the coupling agent is 7-azabenzotriazol-1 -yloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP)/N-methylmorpholine (NMM) (3 fold excess).
  • glutamic acid (E) at position 24 may be substituted with aspartic acid (D) and the aspartic acid cyclized with lysine at position or 28 as described previously.
  • lysine at position 20 or 28 may be substituted with ornithine cyclized with either aspartic acid or glutamic acid at position 24 as described previously. This kind of substitution followed by cyclisation can be done with all analogues described above (SEQ ID No. 67-1 10).
  • lysine (K) at position 20 or 28 may be substituted with ornithine (O) (SEQ ID No. 42 to 73) and ornithine at position 20 or 28 cyclized with glutamic acid (or with substituted aspartic acid (SEQ ID No. 74-89)) at position 24 as described previously.
  • lysine may be substituted by leucine (L), or other hydrophpobic residues such as isoleucine (I), norleucine (NIe), valine (V), alanine (A), tryptophan (W), or phenylalanine (F). Lysine may also be substituted with methionine, however, methionine oxides and forms a disulphide bond making the peptide synthesis and purification more difficult.
  • CXCR4 antatognists of the present invention may further include hydrid analogs comprising N-terminal amino acid residues of SDF-1[P2G] and amino acid residues of MIP-1a that are associated with GAG binding of the chemokine receptor, for example by replacing the relevant SDF-1 GAG-binding sequence, which may not be as specific as that of MlP-1 ⁇ (see Gabriele S. et al., Biochemistry (1999) 38: 12959-12968 and Elisabeth M. et al., Virology (1999) 265, 354-364).
  • SDF-1 derived peptide antagonists of CXCR4 may include peptides that differ from a portion of the native SDF-1 sequence by conservative amino acid substitutions.
  • the present invention also extends biologically equivalent peptides that differ from a portion of the sequence of novel antagonists of the present invention by conservative amino acid substitutions.
  • conservative amino acid substitutions refers to the substitution of one amino acid for another at a given location in the peptide, where the substitution can be made without loss of function.
  • substitutions of like amino acid residues can be made on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing.
  • conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydrophilicity value (e.g., within a value of plus or minus 2.0), where the following hydrophilicity values are assigned to amino acid residues (as detailed in U.S. Pat. No.
  • conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydropathic index (e.g., within a value of plus or minus 2.0).
  • each amino acid residue may be assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics, as follows: lie (+4.5); Val (+4.2); Leu (+3.8); Phe (+2.8); Cys (+2.5); Met (+1.9); Ala (+1.8); Gly ( ⁇ 0.4); Thr ( ⁇ 0.7); Ser ( ⁇ 0.8); Trp ( ⁇ 0.9); Tyr ( ⁇ 1.3); Pro ( ⁇ 1.6); His ( ⁇ 3.2); Glu ( ⁇ 3.5); Gln ( ⁇ 3.5); Asp ( ⁇ 3.5); Asn ( ⁇ 3.5); Lys ( ⁇ 3.9); and Arg ( ⁇ 4.5).
  • conserved amino acid substitutions may be made where an amino acid residue is substituted for another in the same class, where the amino acids are divided into non-polar, acidic, basic and neutral classes, as follows: non-polar: Ala, Val, Leu, lie, Phe, Trp, Pro, Met; acidic: Asp, Glu; basic: Lys, Arg, His; neutral: Gly, Ser, Thr, Cys, Asn, Gln, Tyr.
  • CXCR4 antagonists are ligands that bind to CXCR4 with sufficient affinity and in such a manner so as to inhibit the effects of binding by an agonists, such as the natural ligand SDF-1, such as SDF-1 -induced [Ca2+]i mobilization in cells.
  • an agonists such as the natural ligand SDF-1, such as SDF-1 -induced [Ca2+]i mobilization in cells.
  • SDF-1 such as SDF-1 -induced [Ca2+]i mobilization in cells.
  • Example of CXCR4 antagonist assays may for example be found in International Patent Publications WO 00/09152 (published Feb. 24, 2000) and WO 99/47158 (published Sep. 23, 1999).
  • fura-2,AM loaded THP-1 cells may for example be incubated with putative antagonists, such as for 60 min prior to induction of [Ca2+]i mobilization by 10 nM SDF-1.
  • Antagonists will typically demonstrate a dose responsive inhibition of SDF-1-induced [Ca2+]i mobilization.
  • Methods that may be utilized to determine whether a molecule functions as a CXCR4 antagonists include, but are not limited to, the following: Inhibition of the induction of SDF-1 receptor mediated rise in free cytosolic Ca 2+ concentration ([Ca 2+ ]) in response to native SDF-1 (or agonist analogs of SDF-1) (Loetscher P. et al., (1998) J. Biol. Chem.
  • CXCR4 antagonist may be incubated under the appropriate experimental conditions in the presence of SDF-1, in assays to determine if the CXCR4 antagonist associated repression of the respective mechanism results directly from inhibition of the CXCR4 receptor.
  • mobilization, chemotaxis assays or other assays that measure the induction of CXCR4 are not limited to the cell types indicated in the associated references, but may include other cell types that demonstrate CXCR4 associated, and specific, activation.
  • the invention provides uses for CXCR4 antagonists that are identified as molecules that bind to CXCR4 (whether reversible or irreversible) and are associated with the repression of CXCR4 associated activity. Binding affinity of a CXCR4 antagonists may for example be associated with ligand binding assay dissociation constants (K D ) in the range of a minimum of 1 pM, 10 pM, 100 pM, 1 uM, 10 uM or 100 uM up to a maximum of 1 mM, or any value in any such range.
  • K D ligand binding assay dissociation constants
  • CXCR4 antagonist associated KD values may be determined through alternative approaches, such as standard methods of radioligand binding assays, including High Throughput Fluorescence Polarization, scintillation proximity assays (SPA), and FlashplatesTM® (Allen et al., (2000) J. Biomolecular Screening 5, 63-69), where the competing ligand is native SDF-1.
  • the affinity of a CXCR4 antagonist for the SDF-1 receptor (CXCR4) may be ascertained through inhibition of native SDF-1 binding to the CXCR4, where various concentrations of the CXCR4 antagonist are added in the presence of SDF-1 and a recombinant CXCR4 or a cell type that expresses an adequate receptor titer.
  • the present invention relates to uses of small molecule non-peptide CXCR4 antagonists, such as a naphthoic acid derivative designated herein as 3-hydroxy-2-naphthoic acid (CAS 92-70-6; molecular formula:
  • the invention provides pharmaceutical compositions containing CXCR4 antagonists.
  • such compositions include a CXCR4 antagonist compound in a therapeutically or prophylactically effective amount sufficient to alter bone marrow progenitor or stem cell growth, and a pharmaceutically acceptable carrier.
  • the composition includes a CXCR4 antagonist compound in a therapeutically or prophylactically effective amount sufficient to inhibit a cytotoxic effect of a cytotoxic agent, such as cytotoxic agents used in chemotherapy or radiation treatment of cancer, and a pharmaceutically acceptable carrier.
  • a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reduction of bone marrow progenitor or stem cell multiplication, or reduction or inhibition of a cytotoxic effect of a cytotoxic agent.
  • a therapeutically effective amount of CXCR4 antagonist may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the CXCR4 antagonist to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of the CXCR4 antagonist are outweighed by the therapeutically beneficial effects.
  • a “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as preventing or inhibiting a cytotoxic effect of a cytotoxic agent.
  • a prophylactic dose is used in subjects prior to or at an earlier stage of disease, so that a prophylactically effective amount may be less than a therapeutically effective amount.
  • a preferred range for therapeutically or prophylactically effective amounts of CXCR4 antagonists may be 0.1 nM-0.1M, 0.1 nM-0.05M, 0.05 nM-15 ⁇ M or 0.01 nM-100 ⁇ M. It is to be noted that dosage values may vary with the severity of the condition to be alleviated. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions. Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that may be selected by medical practitioners.
  • the amount of active compound in the composition may vary according to factors such as the disease state, age, sex, and weight of the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It may be advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. “Dosage unit form” as used herein refers to physically discrete units suited as unitary dosages for subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • the carrier is suitable for parenteral administration.
  • the carrier can be suitable for intravenous, intraperitoneal, intramuscular, sublingual or oral administration.
  • Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • CXCR4 agonists may be formulated in pharmaceutical compositions with additional active ingredients, or administered in methods of treatment in conjunction with treatment with one or more additional medications, such as a medicament selected from the following: recombinant-methionyl human G-CSF (Neupogen, Filgastim; Amgen), GM-CSF (Leukine®, Sargramostim; Immunex), erythropoietin (rhEPO, Epogen®; Amgen), thrombopoietin (rhTPO; Genentech), interleukin-11 (rhlL-11, Neumega®; American Home Products), Flt3 ligand (Mobista; Immunex), multilineage hematopoietic factor (MARstemTM; Maret Pharm.), myelopoietin (Leridistem; Searle), IL-3, myeloid progenitor inhibitory factor-1 (Mirostipen; Human Genome Sciences), and stem cell factor (rhS)
  • a medicament selected from
  • compositions typically must be sterile and stable under the conditions of manufacture and storage.
  • the composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin.
  • the CXCR4 antagonists may be administered in a time release formulation, for example in a composition which includes a slow release polymer.
  • the active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • a CXCR4 antagonist may be formulated with one or more additional compounds that enhance the solubility of the CXCR4 antagonist. The invention also extends to such derivatives of novel antagonists of the invention.
  • CXCR4 antagonist compounds of the invention may include SDF-1 derivatives, such as C-terminal hydroxymethyl derivatives, O-modified derivatives (e.g., C-terminal hydroxymethyl benzyl ether), N-terminally modified derivatives including substituted amides such as alkylamides and hydrazides and compounds in which a C-terminal phenylalanine residue is replaced with a phenethylamide analogue (e.g., Ser-Ile-phenethylamide as an analogue of the tripeptide Ser-le-Phe).
  • SDF-1 derivatives such as C-terminal hydroxymethyl derivatives, O-modified derivatives (e.g., C-terminal hydroxymethyl benzyl ether), N-terminally modified derivatives including substituted amides such as alkylamides and hydrazides and compounds in which a C-terminal phenylalanine residue is replaced with a phenethylamide analogue (e.g
  • a peptidic structure such as an SDF-1 derived peptide
  • modifying group is intended to include structures that are directly attached to the peptidic structure (e.g., by covalent coupling), as well as those that are indirectly attached to the peptidic structure (e.g., by a stable non-covalent association or by covalent coupling to additional amino acid residues, or mimetics, analogues or derivatives thereof, which may flank the SDF-1 core peptidic structure).
  • the modifying group can be coupled to the amino-terminus or carboxy-terminus of an SDF-1 peptidic structure, or to a peptidic or peptidomimetic region flanking the core domain.
  • the modifying group can be coupled to a side chain of at least one amino acid residue of a SDF-1 peptidic structure, or to a peptidic or peptido-mimetic region flanking the core domain (e.g., through the epsilon amino group of a lysyl residue(s), through the carboxyl group of an aspartic acid residue(s) or a glutamic acid residue(s), through a hydroxy group of a tyrosyl residue(s), a serine residue(s) or a threonine residue(s) or other suitable reactive group on an amino acid side chain).
  • Modifying groups covalently coupled to the peptidic structure can be attached by means and using methods well known in the art for linking chemical structures, including, for example, amide, alkyla
  • the modifying group may comprise a cyclic, heterocyclic or polycyclic group.
  • cyclic group includes cyclic saturated or unsaturated (i.e., aromatic) group having from 3 to 10, 4 to 8, or 5 to 7 carbon atoms.
  • exemplary cyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Cyclic groups may be unsubstituted or substituted at one or more ring positions.
  • a cyclic group may for example be substituted with halogens, alkyls, cycloalkyls, alkenyls, alkynyls, aryls, heterocycles, hydroxyls, aminos, nitros, thiols amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, sulfonates, selenoethers, ketones, aldehydes, esters, —CF 3 , —CN.
  • heterocyclic group includes cyclic saturated, unsaturated and aromatic groups having from 3 to 10, 4 to 8, or 5 to 7 carbon atoms, wherein the ring structure includes about one or more heteroatoms.
  • Heterocyclic groups include pyrrolidine, oxolane, thiolane, imidazole, oxazole, piperidine, piperazine, morpholine.
  • the heterocyclic ring may be substituted at one or more positions with such substituents as, for example, halogens, alkyls, cycloalkyls, alkenyls, alkynyls, aryls, other heterocycles, hydroxyl, amino, nitro, thiol, amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, —CF 3 , —CN.
  • Heterocycles may also be bridged or fused to other cyclic groups as described below.
  • polycyclic group as used herein is intended to refer to two or more saturated, unsaturated or aromatic cyclic rings in which two or more carbons are common to two adjoining rings, so that the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings.
  • Each of the rings of the polycyclic group may be substituted with such substituents as described above, as for example, halogens, alkyls, cycloalkyls, alkenyls, alkynyls, hydroxyl, amino, nitro, thiol, amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls, ethers, thioethers, sulfonyls, selenoethers, ketones, aldehydes, esters, —CF 3 , or —CN.
  • substituents as described above, as for example, halogens, alkyls, cycloalkyls, alkenyls, alkynyls, hydroxyl, amino, nitro, thiol, amines, imines, amides, phosphonates, phosphines, carbonyls, carboxyls, silyls
  • alkyl refers to the radical of saturated aliphatic groups, including straight chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
  • a straight chain or branched chain alkyl has 20 or fewer carbon atoms in its backbone (C 1 -C 20 for straight chain, C 3 -C 20 for branched chain), or 10 or fewer carbon atom.
  • cycloalkyls may have from 4-10 carbon atoms in their ring structure, such as 5, 6 or 7 carbon rings.
  • lower alkyl as used herein means an alkyl group, as defined above, having from one to ten carbon atoms in its backbone structure. Likewise, “lower alkenyl” and “lower alkynyl” have chain lengths of ten or less carbons.
  • alkyl (or “lower alkyl”) as used throughout the specification and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • substituents can include, for example, halogen, hydroxyl, carbonyl (such as carboxyl, ketones (including alkylcarbonyl and arylcarbonyl groups), and esters (including alkyloxycarbonyl and aryloxycarbonyl groups)), thiocarbonyl, acyloxy, alkoxyl, phosphoryl, phosphonate, phosphinate, amino, acylamino, amido, amidine, imino, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, heterocyclyl, aralkyl, or an aromatic or heteroaromatic moiety.
  • carbonyl such as carboxyl, ketones (including alkylcarbonyl and arylcarbonyl groups), and esters (including alkyloxycarbonyl and aryloxycarbonyl groups)
  • the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
  • the substituents of a substituted alkyl may include substituted and unsubstituted forms of aminos, azidos, iminos, amidos, phosphoryls (including phosphonates and phosphinates), sulfonyls (including sulfates, sulfonamidos, sulfamoyls and sulfonates), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), —CF 3 , —CN and the like. Exemplary substituted alkyls are described below.
  • Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, —CF 3 , —CN, and the like.
  • alkenyl and alkynyl refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
  • aralkyl refers to an alkyl or alkylenyl group substituted with at least one aryl group.
  • exemplary aralkyls include benzyl (i.e., phenylmethyl), 2-naphthylethyl, 2-(2-pyridyl)propyl, 5-dibenzosuberyl, and the like.
  • alkylcarbonyl refers to —C(O)-alkyl.
  • arylcarbonyl refers to -C(O)-aryl.
  • alkyloxycarbonyl refers to the group —C(O)—O-alkyl, and the term “aryloxycarbonyl” refers to —C(O)—O-aryl.
  • acyloxy refers to —O—C(O)—R 7 , in which R 7 is alkyl, alkenyl, alkynyl, aryl, aralkyl or heterocyclyl.
  • amino refers to —N(R ⁇ )(R ⁇ ), in which R ⁇ and R ⁇ are each independently hydrogen, alkyl, alkyenyl, alkynyl, aralkyl, aryl, or in which R ⁇ and R ⁇ together with the nitrogen atom to which they are attached form a ring having 4-8 atoms.
  • amino includes unsubstituted, monosubstituted (e.g., monoalkylamino or monoarylamino), and disubstitited (e.g., dialkylamino or alkylarylamino) amino groups.
  • acylamino refers to —N(R′ 8 )C(O)—R 7 , in which R 7 is as defined above and R′ 8 is alkyl.
  • nitro means —NO 2 ;
  • halogen designates —F, —Cl, —Br or —I;
  • sulfhydryl means —SH; and
  • hydroxyl means —OH.
  • aryl as used herein includes 5-, 6- and 7-membered aromatic groups that may include from zero to four heteroatoms in the ring, for example, phenyl, pyrrolyl, furyl, thiophenyl, imidazolyl, oxazole, thiazolyl, triazolyl, pyrazolyl, pyridyl, pyrazinyl, pyridazinyl and pyrimidinyl, and the like.
  • aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles” or “heteroaromatics”.
  • the aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF 3 , —CN, or the like.
  • Aryl groups can also be part of a polycyclic group.
  • aryl groups include fused aromatic moieties such as naphthyl, anthracenyl, quinolyl, indolyl, and the like.
  • Modifying groups may include groups comprising biotinyl structures, fluorescein-containing groups, a diethylene-triaminepentaacetyl group, a ( ⁇ )-menthoxyacetyl group, a N-acetylneuraminyl group, a cholyl structure or an iminiobiotinyl group.
  • a CXCR4 antagonist compound may be modified at its carboxy terminus with a cholyl group according to methods known in the art (see e.g., Wess, G. et al. (1993) Tetrahedron Letters, 34:817-822; Wess, G. et al. (1992) Tetrahedron Letters 33:195-198; and Kramer, W.
  • Cholyl derivatives and analogues may also be used as modifying groups.
  • a preferred cholyl derivative is Aic (3-(O-aminoethyl-iso)-cholyl), which has a free amino group that can be used to further modify the CXCR4 antagonist compound.
  • a modifying group may be a “biotinyl structure”, which includes biotinyl groups and analogues and derivatives thereof (such as a 2-iminobiotinyl group).
  • the modifying group may comprise a “fluorescein-containing group”, such as a group derived from reacting an SDF-1 derived peptidic structure with 5-(and 6-)-carboxyfluorescein, succinimidyl ester or fluorescein isothiocyanate.
  • a fluorescein-containing group such as a group derived from reacting an SDF-1 derived peptidic structure with 5-(and 6-)-carboxyfluorescein, succinimidyl ester or fluorescein isothiocyanate.
  • the modifying group(s) may comprise an N-acetylneuraminyl group, a trans-4-cotininecarboxyl group, a 2-imino-1-imidazolidineacetyl group, an (S)-( ⁇ )-indoline-2-carboxyl group, a ( ⁇ )-menthoxyacetyl group, a 2-norbornaneacetyl group, a -oxo-5-acenaphthenebutyryl, a ( ⁇ )-2-oxo-4-thiazolidinecarboxyl group, a tetrahydro-3-furoyl group, a 2-iminobiotinyl group, a diethylenetriaminepentaacetyl group, a 4-morpholinecarbonyl group, a 2-thiopheneacetyl group or a 2-thiophenesulfonyl group.
  • a CXCR4 antagonist compound of the invention may be further modified to alter the specific properties of the compound while retaining the desired functionality of the compound.
  • the compound may be modified to alter a pharmacokinetic property of the compound, such as in vivo stability, bioavailability or half-life.
  • the compound may be modified to label the compound with a detectable substance.
  • the compound may be modified to couple the compound to an additional therapeutic moiety.
  • reactive groups can be derivatized. For example, when the modifying group is attached to the amino-terminal end of the SDF-1 core domain, the carboxy-terminal end of the compound may be further modified.
  • C-terminal modifications include those that reduce the ability of the compound to act as a substrate for carboxypeptidases.
  • C-terminal modifiers include an amide group, an ethylamide group and various non-natural amino acids, such as D-amino acids and ⁇ -alanine.
  • the amino-terminal end of the compound may be further modified, for example, to reduce the ability of the compound to act as a substrate for aminopeptidases.
  • a CXCR4 antagonist compound can be further modified to label the compound by reacting the compound with a detectable substance.
  • Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin
  • an example of a luminescent material includes luminol
  • suitable radioactive material include 14 C, 123 I, 124 I, 125 I, 131 I, 99m Tc, 35 S or 3 H.
  • a CXCR4 antagonist compound may be radioactively labeled with 14 C, either by incorporation of 14 C into the modifying group or one or more amino acid structures in the CXCR4 antagonist compound.
  • Labeled CXCR4 antagonist compounds may be used to assess the in vivo pharmacokinetics of the compounds, as well as to detect disease progression or propensity of a subject to develop a disease, for example for diagnostic purposes.
  • Tissue distribution CXCR4 receptors can be detected using a labeled CXCR4 antagonist compound either in vivo or in an in vitro sample derived from a subject.
  • a CXCR4 antagonist compound of the invention may be labeled with radioactive technetium or iodine.
  • a modifying group can be chosen that provides a site at which a chelation group for the label can be introduced, such as the Aic derivative of cholic acid, which has a free amino group.
  • a phenylalanine residue within the SDF-1 sequence (such as amino acid residue 13) may be substituted with radioactive iodotyrosyl. Any of the various isotopes of radioactive iodine may be incorporated to create a diagnostic agent.
  • a CXCR4 antagonist compound of the invention may be prepared in a “prodrug” form, wherein the compound itself does not act as a CXCR4 antagonist, but rather is capable of being transformed, upon metabolism in vivo, into a CXCR4 antagonist compound as defined herein.
  • the modifying group can be present in a prodrug form that is capable of being converted upon metabolism into the form of an active CXCR4 antagonist.
  • Such a prodrug form of a modifying group is referred to herein as a “secondary modifying group.”
  • a variety of strategies are known in the art for preparing peptide prodrugs that limit metabolism in order to optimize delivery of the active form of the peptide-based drug (see e.g., Moss, J. (1995) in Peptide-Based Drug Design: Controlling Transport and Metabolism, Taylor, M. D. and Amidon, G. L. (eds), Chapter 18.
  • CXCR4 antagonist compounds of the invention may be prepared by standard techniques known in the art.
  • a peptide component of a CXCR4 antagonist may be composed, at least in part, of a peptide synthesized using standard techniques (such as those described in Bodansky, M. Principles of Peptide Synthesis, Springer Verlag, Berlin (1993); Grant, G. A. (ed.). Synthetic Peptides: A User's Guide, W. H. Freeman and Company, New York (1992); or Clark-Lewis, I., Dewald, B., Loetscher, M., Moser, B., and Baggiolini, M., (1994) J. Biol. Chem., 269, 16075-16081).
  • Peptides may be assayed for CXCR4 antagonist activity in accordance with standard methods. Peptides may be purified by HPLC and analyzed by mass spectrometry. Peptides may be dimerized via a disulfide bridge formed by gentle oxidation of the cysteines using 10% DMSO in water. Following HPLC purification dimer formation may be verified, by mass spectrometry.
  • One or more modifying groups may be attached to a SDF-1 derived peptidic component by standard methods, for example using methods for reaction through an amino group (e.g., the alpha-amino group at the amino-terminus of a peptide), a carboxyl group (e.g., at the carboxy terminus of a peptide), a hydroxyl group (e.g., on a tyrosine, serine or threonine residue) or other suitable reactive group on an amino acid side chain (see e.g., Greene, T. W. and Wuts, P. G. M. Protective Groups in Organic Synthesis, John Wiley and Sons, Inc., New York (1991)).
  • an amino group e.g., the alpha-amino group at the amino-terminus of a peptide
  • a carboxyl group e.g., at the carboxy terminus of a peptide
  • a hydroxyl group e.g., on a
  • CXCR4 antagonist peptides may be prepared according to standard recombinant DNA techniques using a nucleic acid molecule encoding the peptide.
  • a nucleotide sequence encoding the peptide may be determined using the genetic code and an oligonucleotide molecule having this nucleotide sequence may be synthesized by standard DNA synthesis methods (e.g., using an automated DNA synthesizer).
  • a DNA molecule encoding a peptide compound may be derived from the natural precursor protein gene or cDNA (e.g., using the polymerase chain reaction (PCR) and/or restriction enzyme digestion) according to standard molecular biology techniques.
  • PCR polymerase chain reaction
  • the invention also provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a peptide of the invention.
  • the peptide may comprise an amino acid sequence having at least one amino acid deletion compared to native SDF-1.
  • the term “nucleic acid molecule” is intended to include DNA molecules and RNA molecules and may be single-stranded or double-stranded.
  • the isolated nucleic acid encodes a peptide wherein one or more amino acids are deleted from the N-terminus, C-terminus and/or an internal site of SDF-1.
  • the isolated nucleic acid encoding the peptide may be incorporated into a recombinant expression vector.
  • the invention also provides recombinant expression vectors comprising the nucleic acid molecules of the invention.
  • the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been operatively linked.
  • Vectors may include circular double stranded DNA plasmids, viral vectors.
  • Certain vectors are capable of autonomous replication in a host cell into which they are introduced (such as bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
  • vectors such as non-episomal mammalian vectors
  • Other vectors may be integrated into the genome of a host cell upon introduction into the host cell, and thereby may be replicated along with the host genome.
  • Certain vectors may be capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” or “expression vectors”.
  • the nucleotide sequence encoding a peptide may be operatively linked to one or more regulatory sequences, selected on the basis of the host cells to be used for expression.
  • operatively linked or “operably” linked mean that the sequences encoding the peptide are linked to the regulatory sequence(s) in a manner that allows for expression of the peptide compound.
  • regulatory sequence includes promoters, enhancers, polyadenylation signals and other expression control elements. Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) (incorporated herein be reference).
  • Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell, those that direct expression of the nucleotide sequence only in certain host cells (such as tissue-specific regulatory sequences) and those that direct expression in a regulatable manner (such as only in the presence of an inducing agent).
  • the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and the level of expression of peptide compound desired.
  • the recombinant expression vectors of the invention may be designed for expression of peptide compounds in prokaryotic or eukaryotic cells.
  • peptide compounds may be expressed in bacterial cells such as E. coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990).
  • the recombinant expression vector may be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase. Examples of vectors for expression in yeast S.
  • cerivisae examples include pYepSec1 (Baldari et al., (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.).
  • Baculovirus vectors available for expression of proteins or peptides in cultured insect cells include the pAc series (Smith et al., (1983) Mol. Cell. Biol. 3:2156-2165) and the pVL series (Lucklow, V.
  • mammalian expression vectors include pCDM8 (Seed, B., (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987), EMBO J. 6:187-195).
  • the expression vector's control functions are often provided by viral regulatory elements.
  • commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.
  • recombinant expression vectors may contain additional nucleotide sequences, such as a selectable marker gene to identify host cells that have incorporated the vector. Selectable marker genes are well known in the art.
  • the recombinant expression vector preferably encodes a signal sequence operatively linked to sequences encoding the amino-terminus of the peptide compound, such that upon expression, the peptide compound is synthesised with the signal sequence fused to its amino terminus.
  • This signal sequence directs the peptide compound into the secretory pathway of the cell and is then cleaved, allowing for release of the mature peptide compound (i.e., the peptide compound without the signal sequence) from the host cell.
  • a signal sequence to facilitate secretion of proteins or peptides from mammalian host cells is well known in the art.
  • a recombinant expression vector comprising a nucleic acid encoding a peptide compound may be introduced into a host cell to produce the peptide compound in the host cell.
  • the invention also provides host cells containing the recombinant expression vectors of the invention.
  • the terms “host cell” and “recombinant host cell” are used interchangeably herein. Such terms refer not only to the particular subject cell but to the progeny or potential progeny of surh a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
  • a host cell may be any prokaryotic or eukaryotic cell.
  • a peptide compound may be expressed in bacterial cells such as E. coli , insect cells, yeast or mammalian cells.
  • the peptide compound may be expressed in vivo in a subject to the subject by gene therapy (discussed further below).
  • Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation, transfection or infection techniques.
  • transformation transformation or transformation or infection refer to techniques for introducing foreign nucleic acid into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, microinjection and viral-mediated infection. Suitable methods for transforming, transfecting or infecting host cells can for example be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory manuals. Methods for introducing DNA into mammalian cells in vivo are also known, and may be used to deliver the vector DNA of the invention to a subject for gene therapy.
  • a gene that encodes a selectable marker (such as resistance to antibiotics) may be introduced into the host cells along with the gene of interest.
  • selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate.
  • Nucleic acids encoding a selectable marker may be introduced into a host cell on the same vector as that encoding the peptide compound or may be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid may be identified by drug selection (cells that have incorporated the selectable marker gene will survive, while the other cells die).
  • a nucleic acid of the invention may be delivered to cells in vivo using methods such as direct injection of DNA, receptor-mediated DNA uptake or viral-mediated transfection.
  • Direct injection has been used to introduce naked DNA into cells in vivo (see e.g., Acsadi et al. (1991) Nature 332:815-818; Wolff et al. (1990) Science 247:1465-1468).
  • a delivery apparatus e.g., a “gene gun” for injecting DNA into cells in vivo may be used.
  • Such an apparatus may be commercially available (e.g., from BioRad).
  • Naked DNA may also be introduced into cells by complexing the DNA to a cation, such as polylysine, which is coupled to a ligand for a cell-surfacc receptor (see for example Wu, G. and Wu, C. H. (1988) J. Biol. Chem. 263:14621; Wilson el al. (1992) J. Biol. Chem. 267:963-967; and U.S. Pat. No. 5,166,320). Binding of the DNA-ligand complex to the receptor may facilitate uptake of the DNA by receptor-mediated endocytosis.
  • a cation such as polylysine
  • a DNA-ligand complex linked to adenovirus capsids which disrupt endosomes, thereby releasing material into the cytoplasm may be used to avoid degradation of the complex by intracellular lysosomes (see for example Curiel el al. (1991) Proc. Natl. Acad. Sci. USA 88:8850; Cristiano et al. (1993) Proc. Natl. Acad. Sci. USA 90:2122-2126).
  • Defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for reviews see Miller, A. D. (1990) Blood 76:271, Kume et al. (1999) International. J. Hematol. 69:227-233). Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM, which are well known to those skilled in the art.
  • Suitable packaging virus lines include .p ⁇ i.Crip, .p ⁇ i.Cre, .p ⁇ i.2 and .p ⁇ i.Am.
  • Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464; Wilson et al. (1988) Proc. Natl. Acad. Sci.
  • a genome of a retrovirus that encodes and expresses a polypeptide compound of the invention may be utilized for the propagation and/or survival of cells, such as hematopoietic progenitor stem cells, for the purposes of maintaining and/or growing cells for the clinical purposes of blood transfusion or engraftment, host conditioning or applications relevant to chemotherapy, radiation therapy or myeloablative therapy.
  • cells such as hematopoietic progenitor stem cells
  • an adenovirus For use as a gene therapy vector, the genome of an adenovirus may be manipulated so that it encodes and expresses a peptide compound of the invention, but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See for example Berkner et al. (1988) BioTechniques 6:616; Rosenfeld et al. (1991) Science 252:431-434; and Rosenfeld et al. (1992) Cell 68:143-155.
  • Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus are well known to those skilled in the art.
  • Recombinant adenoviruses are advantageous in that they do not require dividing cells to be effective gene delivery vehicles and can be used to infect a wide variety of cell types, including airway epithelium (Rosenfeld et al. (1992) cited supra), endothelial cells (Lemarchand et al. (1992) Proc. Natl. Acad. Sci. USA 89:6482-6486), hepatocytes (Herz and Gerard (1993) Proc. Natl. Acad. Sci. USA 90:2812-2816) and muscle cells (Quantin el al. (1992) Proc. Natl. Acad. Sci. USA 89:2581-2584).
  • a genome of an adenovirus that encodes and expresses a polypeptide compound of the invention may be utilized for the propagation and/or survival of cells, such as hematopoietic progenitor stem cells, stromal cells, or mesenchymal cells, for the purposes of maintaining and/or growing cells for the clinical purposes of blood transfusion or engraftment, host conditioning or applications relevant to chemotherapy, radiation therapy or myeloablative therapy.
  • cells such as hematopoietic progenitor stem cells, stromal cells, or mesenchymal cells
  • adeno-associated virus may be used as a gene therapy vector for delivery of DNA for gene therapy purposes.
  • AAV is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al. Curr. Topics in Micro. and Immunol. (1992) 158:97-129).
  • AAV may be used to integrate DNA into non-dividing cells (see for example Flotte et al. (1992) Am. J. Respir. Cell. Mol. Biol. 7:349-356; Samulski et al. (1989) J. Virol.
  • An MV vector such as that described in Tratschin et al. (1985) Mol. Cell. Biol. 5:3251-3260 may be used to introduce DNA into cells (see for example Hermonat et al. (1984) Proc. Natl. Acad. Sci. USA 81:6466-6470; Tratschin et al. (1985) Mol. Cell. Biol. 4:2072-2081; Wondisford et al. (1988) Mol. Endocrinol. 2:32-39; Tratschin et al. (1984) J. Virol.
  • a genome of an MV that encodes and expresses a polypeptide compound of the invention may be utilized for the propagation and/or survival of cells, such as hematopoietic progenitor stem cells, stromal cells or mesenchymal cells, for the purposes of maintaining and/or growing cells for the clinical purposes of blood transfusion or engraftment, host conditioning or applications relevant to chemotherapy, radiation therapy or myeloablative therapy.
  • cells such as hematopoietic progenitor stem cells, stromal cells or mesenchymal cells
  • Cancers susceptible to treatment with CXCR4 antagonists in accordance with various aspects of the invention may include both primary and metastatic tumors, such as solid tumors, including carcinomas of the breast, colon, rectum, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gall bladder and bile ducts, small intestine, urinary tract (including kidney, bladder, and urothelium), female genital tract (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblast disease), male genital tract (including prostate, seminal vesicles, testes, and germ cell tumors), endocrine glands (including the thyroid, adrenal and pituitary glands), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well as Kaposi's sarcoma) and tumors of the brain,
  • CXCR4 antagonists may also serve in treating solid tumors arising from hematopoietic malignancies such as leukemias (i.e., chloromas, plasmacytomas and the plaques and tumors of mycosis fungoides and cutaneous T-cell lymphoma/leukemia) as well as in the treatment of lymphoma (both Hodgkin's and non-Hodgkin's lymphomas).
  • CDCR4 antagonists may be therapeutic in the prevention of metastasis from the tumors described above either when used alone or in combination with cytotoxic agents such as radiotherapy or chemotherapeutic agents (for instance refer to Zlotnik et al., Nature 410, 50-56, 2001).
  • CXCR4 antagonists such as SDF-1 polypeptides and non-peptide small molecule antagonists may target CD34 + cells to mediate release of CD34 + cells to the peripheral blood.
  • CXCR4 antagonists may enhance circulating CD34 + cell proliferation and hematopoietic stem or progenitor cell survival or levels, which may for example be useful in stem cell transplantation or ex vivo expansion.
  • CXCR4 antagonists may enhance hematopoietic stem or progenitor cell mobilization.
  • CXCR4 antagonists may be used in maintaining or augmenting the rate of hematopoietic cell multiplication.
  • Method of the invention may comprise administration of an effective amount of CXCR4 antagonists to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells, stromal cells or mesenchymal cells.
  • a therapeutically effective amount of the CXCR4 antagonist may be administered to a patient in need of such treatment.
  • Patients in need of such treatments may include, for example: patients having cancer, patients having an autoimmune disease, patients requiring functional gene transfer into hematopoietic stems cells, stromal cells or mesenchymal cells (such as for the dysfunction of any tissue or organ into which a stem cell may differentiate), patients requiring lymphocyte depletion, patients requiring depletion of a blood cancer in the form of purging autoreactive or cancerous cells using autologous or aligenic grafts, or patients requiring autologous peripheral blood stem cell transplantation.
  • a patient in need of treatment in accordance with the invention may also be receiving cytotoxic treatments such as chemotherapy or radiation therapy.
  • CXCR4 antagonists may be used in treatment to purge an ex vivo hematopoietic stem cell culture of cancer cells with cytotoxic treatment, while preserving the viability and self-renewal of the hematopoietic progenitor or stem cells.
  • the methods of treatment of the invention may be utilized where a patient is undergoing myelosuppressive treatment causing hematopoietic cell depletion, including pancytopenia, granulocytopenia, thrombocytopenia, anemia or a combination thereof.
  • the patient to be treated may be suffering from AIDS, and the treatment may for example be effected to augment hematopoietic cell counts.
  • FIG. 1 shows the results of CXCR4 receptor binding assay.
  • antagonists comprising ligands (20 M) were added to 5 ⁇ 10 6 CEM cell/ml in the presence of 4 nM 1251-SDF-1.
  • CEM cells were assessed for 125I-SDF-1 binding following 2 hr incubation. The results are expressed as percentages of the maximal specific binding in the absence of a competing ligand, and are the mean of three independent experiments.
  • CTCE0012 KGVSLSYRCPCRFFESHVARANVKHLKILNTPACALQIVARLKNNNRQVCIDPKLKWI QEYLEKALN-COOH
  • CTCE9908 [KGVSLSYR] 2 -K—CONH 2 CTCE9907: KGVSLSYRC(CONH 2 )-(CONH 2 )RYSLSVGK
  • CTCE0014 KGVSLSYRCPCRFF-GGGG- LKWIQEYLEKALN- COOH
  • CTCE0018 KGVSLSYRCPCRFF-GGGG- LKWIQEYLEKALN- CONH 2 CTCE0019: KGVSLSYRCPCRFF-GGGG- LKWIQEYLEKALN- CONH 2 K20/E24 lactamization
  • CTCE0020 KGVSLSYRCPCRFF-GGGG- LKWIQEYLEKALN- CONH 2 K28/E24 lactamization
  • CTCE0016 KGVSLSYRCPCRFFESHVARAN
  • Table 1 shows the effect of CXCR4 antagonists on hematopoietic cells, particularly primitive erythroide cells and primitive granulocytes (hematopoietic progenitor cells), compared to mature granulocytes.
  • cells were pre-incubated with each of the compounds or saline alone (as control). The cells were then exposed to high dose H 3 -thymidine, a cytotoxic agent. Rapidly dividing cells accumulate proportionally more of the cytotoxic radioactive thymidine and as a result are preferentially killed.
  • the relative proportion of cells killed by the thymidine treatment compared to the control is indicative of the relative effectiveness of the compounds in increasing cellular multiplication, i.e.
  • BFU-E CFU-GM None 10 3 +/ ⁇ 2 3 +/ ⁇ 3 SDF-1 (G2) 10 48 +/ ⁇ 5 38 +/ ⁇ 4 CTCE9907 50 39 +/ 7 28 +/ ⁇ 6 CTCE9908 50 51 +/ ⁇ 7 36 +/ ⁇ 6 CTCE0012 10 60 +/ ⁇ 8 44 +/ ⁇ 4 CTCE0016 10 63 +/ ⁇ 5 54 +/ ⁇ 4 CTCE0017 50 57 +/ ⁇ 3 52 +/ ⁇ 6
  • SDF-1 is the peptide KGVSLSYRCPCRFFESHVARANVKHLKILNTPACALQIVARLKNNNRQVCIDPKLKWIQEYLEKALN-COOH
  • CTCE9907 is the peptide [KGVSLSYRC-CONH 2 ] 2
  • CTCE9908 is the peptide [KGVSLSYR] 2 K-CONH 2
  • CTCE0012 is the peptide KGVSLSYRCPCRFFESHVARANVKHLKILNTPACALQIVARLKNNNRQVCIDPKLKWIQEYLEKALN-COOH
  • CTCE0016 is the peptide KGVSLSYRCPCRFFESH-GGGG-LKWIQEYLEKALN-COOH
  • CTCE0017 is the peptide KGVSLSYRCPCRFF-GGGG-LKWIQEYLEKALN-CONH 2
  • FIG. 2 shows the efficacy of CXCR4 antagonists on enhancing the proliferation of human progenitor cells in an in vivo engraftment model.
  • CFU-GM colony forming unit-granulocyte-monocyte precursor, BFU-E; burst forming unit-erythroid precursor
  • LTC-IC long-term culture initiating cell
  • SDF-1 peptide antagonists are effective at enhancing the proliferation of “primitive” human progenitor cells, as measured by the reduction of cells killed by exposure to high specific activity 3 H-thymidine (which only affects proliferating cells).
  • CTCE9907 is the peptide [KGVSLSYRC-CONH 2 ] 2
  • CTCE9908 is the peptide [KGVSLSYR] 2 K-CONH 2
  • CTCE0012 is the peptide KGVSLSYRCPCRFFESHVARANVKHLKILNTPACALQIVARLKNNNRQVCIDPKLKWQEYLEKALN-COOH
  • CTCE0016 is the peptide KGVSLSYRCPCRFFESH-GGGG-LKWIQEYLEKALN-COOH
  • CTCE0017 is the peptide KGVSLSYRCPCRFF-GGGG-LKWIQEYLEKALN-CONH 2
  • FIG. 3. This example illustrates the effect of CXCR4 peptide antagonists on the engraftment of human cells in human fetal liver transplanted NODISCID mice.
  • Administration of 0.5 mg/kg of SDF-1 had no significant effect on the number of CD45/71, CD19/20, or CD34 cells, nor on the CFC or LTC-IC.
  • none of the human cell types were detectably affected by this schedule of CXCR4 agonist administration.
  • SDF-1 peptide antagonists may effectively augment secondary engraftment of human progenitor cells, and that these compounds are essentially not toxic to the animals at the indicated doses.
  • CTCE9907 is the peptide [KGVSLSYRC-CONH 2 ] 2
  • CTCE9908 is the peptide [KGVSLSYR] 2 K-CONH 2
  • CTCE0012 is the peptide KGVSLSYRCPCRFFESHVARANVKHLKILNTPACALQIVARLKNNNRQVCIDPKLKWIQEYLEKALN-COOH
  • CTCE0016 is the peptide KGVSLSYRCPCRFFESH-GGGG-LKWIQEYLEKALN-COOH
  • CTCE0017 is the peptide KGVSLSYRCPCRFF-GGGG-LKWIQEYLEKALN-CONH 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
US09/852,424 1998-03-13 2001-05-09 CXCR4 antagonist treatment of hematopoietic cells Abandoned US20020156034A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US09/852,424 US20020156034A1 (en) 2000-05-09 2001-05-09 CXCR4 antagonist treatment of hematopoietic cells
US10/945,674 US7435718B2 (en) 2000-05-09 2004-09-20 CXCR4 antagonist treatment of hematopoietic cells
US11/649,928 US20070160574A1 (en) 2000-04-12 2007-01-04 Design of CXC chemokine analogs for the treatment of human diseases
US11/752,725 US20080318855A1 (en) 1998-03-13 2007-05-23 Dna encoding for recombinant polypeptide emutants of human stromal cell-derived factor 1
US12/189,764 US20090192082A1 (en) 2000-05-09 2008-08-11 Cxcr4 antagonist treatment of hematopoietic cells
US12/646,921 US20110118193A1 (en) 2000-05-09 2009-12-23 Treatment of liquid cancers
US12/646,915 US20110230422A1 (en) 2000-05-09 2009-12-23 Purging of an ex vivo hematopoietic stem cell culture of cancer cells
US12/883,142 US20110002885A1 (en) 1998-03-13 2010-09-15 Methods of using isolated recombinant polypeptide antagonists of sdf-1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002305787A CA2305787A1 (fr) 2000-05-09 2000-05-09 Traitement antagoniste cxcr4 de cellules hematopoietiques
CA2,305,787 2000-05-09
US20546700P 2000-05-19 2000-05-19
US09/852,424 US20020156034A1 (en) 2000-05-09 2001-05-09 CXCR4 antagonist treatment of hematopoietic cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/060,031 Continuation-In-Part US7354899B2 (en) 1998-03-13 2005-02-16 Methods of treating autoimmune diseases comprising administering CXCR4 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/945,674 Continuation US7435718B2 (en) 1998-03-13 2004-09-20 CXCR4 antagonist treatment of hematopoietic cells

Publications (1)

Publication Number Publication Date
US20020156034A1 true US20020156034A1 (en) 2002-10-24

Family

ID=4165909

Family Applications (5)

Application Number Title Priority Date Filing Date
US09/852,424 Abandoned US20020156034A1 (en) 1998-03-13 2001-05-09 CXCR4 antagonist treatment of hematopoietic cells
US10/945,674 Expired - Fee Related US7435718B2 (en) 1998-03-13 2004-09-20 CXCR4 antagonist treatment of hematopoietic cells
US12/189,764 Abandoned US20090192082A1 (en) 2000-05-09 2008-08-11 Cxcr4 antagonist treatment of hematopoietic cells
US12/646,921 Abandoned US20110118193A1 (en) 2000-05-09 2009-12-23 Treatment of liquid cancers
US12/646,915 Abandoned US20110230422A1 (en) 2000-05-09 2009-12-23 Purging of an ex vivo hematopoietic stem cell culture of cancer cells

Family Applications After (4)

Application Number Title Priority Date Filing Date
US10/945,674 Expired - Fee Related US7435718B2 (en) 1998-03-13 2004-09-20 CXCR4 antagonist treatment of hematopoietic cells
US12/189,764 Abandoned US20090192082A1 (en) 2000-05-09 2008-08-11 Cxcr4 antagonist treatment of hematopoietic cells
US12/646,921 Abandoned US20110118193A1 (en) 2000-05-09 2009-12-23 Treatment of liquid cancers
US12/646,915 Abandoned US20110230422A1 (en) 2000-05-09 2009-12-23 Purging of an ex vivo hematopoietic stem cell culture of cancer cells

Country Status (2)

Country Link
US (5) US20020156034A1 (fr)
CA (1) CA2305787A1 (fr)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148940A1 (en) * 2000-04-12 2003-08-07 Tudan Christopher R. CXCR4 agonist treatment of hematopoietic cells
US6649189B2 (en) * 2000-06-26 2003-11-18 Rxkinetix, Inc. Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells
WO2005002522A2 (fr) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions et methodes pour traiter une ischemie tissulaire
US20050043367A1 (en) * 2001-07-31 2005-02-24 Gary Bridger Methods to mobilize progenitor/stem cells
US6946445B1 (en) * 1998-03-13 2005-09-20 The University Of British Columbia Therapeutic chemokine receptor antagonists
US20060014682A1 (en) * 2000-05-09 2006-01-19 Chemokine Therapeutics Corporation CXCR4 antagonist treatment of hematopoietic cells
US7091310B2 (en) 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
US20060193826A1 (en) * 2001-07-31 2006-08-31 Anormed Inc. Methods to mobilize progenitor/stem cells
US20060252687A1 (en) * 2000-09-14 2006-11-09 Chemokine Therapeutics Corp. Novel chemokine mimetics synthesis and their use
US20060275316A1 (en) * 2002-12-13 2006-12-07 Case Western Reserve University Modulation of cxcr4 and related methods and compositions
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
WO2007036036A1 (fr) * 2005-09-29 2007-04-05 British Columbia Cancer Agency Branch Methode et composition pour moduler une greffage de cellules souches
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
US7354899B2 (en) 1998-08-14 2008-04-08 The University Of British Columbia Methods of treating autoimmune diseases comprising administering CXCR4 antagonists
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US20100143334A1 (en) * 2006-12-21 2010-06-10 Amnon Peled T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
US20100222256A1 (en) * 2000-09-05 2010-09-02 Nobutaka Fujii Novel polypeptide anti-HIV agent containing the same
WO2010146578A3 (fr) * 2009-06-14 2011-02-10 Biokine Therapeutics Ltd. Thérapie à base de peptides pour augmenter les niveaux de plaquettes
EP2397148A2 (fr) 2006-02-02 2011-12-21 Allergan, Inc. Compositions et procédés pour le traitement d'une maladie ophtalmique
WO2012095849A1 (fr) 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides et compositions pour le traitement de tumeurs issues du neuroectoderme et de rétinoblastomes
US8410059B2 (en) 2002-08-27 2013-04-02 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
WO2013160895A1 (fr) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides et leur utilisation dans le traitement du cancer du poumon à grandes cellules
WO2014155376A1 (fr) 2013-03-24 2014-10-02 Biokine Therapeutics Ltd. Méthodes de traitement de la leucémie myéloïde
WO2015063768A1 (fr) 2013-10-31 2015-05-07 Biokine Therapeutics Ltd. Méthodes de traitement de la leucémie myéloïde aiguë avec mutation de la flt3
WO2015114638A2 (fr) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Méthode d'élimination de cellules souches
WO2019097514A1 (fr) 2017-11-14 2019-05-23 Yeda Research And Development Co. Ltd. Cellules souches hématopoïétiques présentant des propriétés améliorées
WO2020065647A1 (fr) 2018-09-25 2020-04-02 Biolinerx Ltd. Procédés de sélection d'un traitement contre un cancer associé aux récepteurs cxcr4
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10993985B2 (en) 2016-02-23 2021-05-04 BioLmeRx Ltd. Methods of treating acute myeloid leukemia

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2009108360A2 (fr) * 2008-02-29 2009-09-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibition de la croissance tumorale post-radique
US20140086901A1 (en) * 2008-02-29 2014-03-27 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Post-Radiation Tumor Growth
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
WO2011053700A1 (fr) * 2009-10-28 2011-05-05 Henry Ford Health System Méthodes d'atténuation des lésions causées par une irradiation
WO2011106234A1 (fr) 2010-02-25 2011-09-01 Provasculon, Inc. Mutants résistant aux protéases du facteur-1 issu des cellules stromales dans réparation de lésions tissulaires
WO2012170495A1 (fr) 2011-06-07 2012-12-13 Provasculon, Inc. Procédés de réparation de dommage tissulaire à l'aide de mutants résistant aux protéases du facteur 1 dérivé de cellules stromales
WO2015031722A1 (fr) 2013-08-30 2015-03-05 Ramot At Tel-Aviv University Ltd. Méthode pour traiter la sclérose latérale amyotrophique par inhibition de la signalisation cxcr4/cxcl12
US11278572B2 (en) * 2014-07-18 2022-03-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
CA3045302A1 (fr) * 2016-11-29 2018-06-07 Health Research, Inc. Procedes et compositions pour une therapie anticancereuse

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2760992A (en) * 1956-08-28 Naphthalene
US2530369A (en) * 1948-01-29 1950-11-21 Phillips Petroleum Co Oxidation of aromatic compounds
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU6131086A (en) * 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
WO1989002468A1 (fr) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Fibroblastes transduits et leurs applications
DE3851153T2 (de) 1987-12-11 1995-01-05 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE124421T1 (de) 1989-09-25 1995-07-15 Genetics Inst Verfahren zur wachstumshemmung von stammzellen.
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
WO1992007943A1 (fr) 1990-10-31 1992-05-14 Somatix Therapy Corporation Vecteurs de retrovirus efficaces en therapie genique
US5401651A (en) * 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
ATE175442T1 (de) 1991-11-15 1999-01-15 Univ California Therapie des zentralnervensystems mit genetisch modifizierten zellen
NZ246354A (en) * 1991-12-23 1995-10-26 British Bio Technology Stem cell inhibiting proteins and their production and use
CN1089344C (zh) * 1993-03-31 2002-08-21 普罗神经细胞有限公司 干细胞增生的抑制剂及其应用
DK0802800T3 (da) 1993-08-12 2002-10-07 Neurotech Sa Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler
CN1136327A (zh) 1993-09-28 1996-11-20 综合医院公司 用反义寡核苷酸调节神经生长并使β/A4淀粉样肽诱导的形态逆转
CA2117953C (fr) * 1993-10-14 2001-12-11 Tasuku Honjo Derive de la stromale humaine facteur 1 aplha et 1 beta et adn encodant ceux-ci
JP3532570B2 (ja) * 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
ATE216425T1 (de) * 1994-08-13 2002-05-15 Roche Diagnostics Gmbh Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen
US5990163A (en) * 1995-01-13 1999-11-23 The Salk Institute For Biological Studies Selective modulation of processes mediated by retinoid X receptors, and compounds useful therefor
US6221361B1 (en) 1995-01-19 2001-04-24 Syntro Corporation Recombinant swinepox virus
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
JPH09206071A (ja) 1996-01-29 1997-08-12 Novo Nordisk As バクテリア由来の酸化酵素
WO1997028258A1 (fr) 1996-01-30 1997-08-07 The National Institutes Of Health Cellules exprimant les molecules humaines cd4 et cxcr4
IL127666A0 (en) * 1996-06-27 1999-10-28 Smithkline Beecham Corp IL-8 receptor antagonists
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
FR2751658B1 (fr) 1996-07-26 1998-10-02 Pasteur Institut Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
AU4251197A (en) 1996-09-06 1998-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Therapeutic chemokine antagonists
US5962462A (en) * 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
IT1291353B1 (it) 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
US6136827A (en) * 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6013644A (en) * 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6140349A (en) * 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
CA2305787A1 (fr) * 2000-05-09 2001-11-09 The University Of British Columbia Traitement antagoniste cxcr4 de cellules hematopoietiques
WO2000009152A1 (fr) 1998-08-14 2000-02-24 The University Of British Columbia Antagonistes therapeutiques du recepteur de la chimiokine
CA2245224A1 (fr) * 1998-08-14 2000-02-14 Jiang-Hong Giong Antagonistes du recepteur de la chimiokine et chimiotherapie
JP2002506830A (ja) 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト
US6613742B1 (en) * 1999-04-07 2003-09-02 Thomas Jefferson University Chemokine-derived synthetic peptides
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
US6356887B1 (en) * 1999-06-28 2002-03-12 Microsoft Corporation Auto-parameterization of database queries
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7091310B2 (en) 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
CA2335109A1 (fr) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Traitement de cellules hematopoietiques avec des agonistes du cxcr4
AU2001258110B2 (en) 2000-05-09 2006-10-19 British Canadian Biosciences Corp. Cxcr4 antagonist treatment of hematopoietic cells
US6515001B2 (en) * 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
US20030004136A1 (en) * 2001-03-05 2003-01-02 Geeta Saxena IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
US6693134B2 (en) * 2001-05-29 2004-02-17 Chemokine Therapeutics Corporation Bicyclic aromatic chemokine receptor ligands
US6831101B2 (en) * 2001-06-14 2004-12-14 Chemokine Therapeutics Corporation Tricyclic rantes receptor ligands
US20030092674A1 (en) * 2001-06-14 2003-05-15 Geeta Saxena Tricyclic rantes receptor ligands

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050265969A1 (en) * 1998-03-13 2005-12-01 The University Of British Columbia Therapeutic chemokine receptor antagonists
US7423011B2 (en) 1998-03-13 2008-09-09 The University Of British Columbia Therapeutic chemokine receptor antagonists
US6946445B1 (en) * 1998-03-13 2005-09-20 The University Of British Columbia Therapeutic chemokine receptor antagonists
US7354899B2 (en) 1998-08-14 2008-04-08 The University Of British Columbia Methods of treating autoimmune diseases comprising administering CXCR4 antagonists
US20030148940A1 (en) * 2000-04-12 2003-08-07 Tudan Christopher R. CXCR4 agonist treatment of hematopoietic cells
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7435718B2 (en) 2000-05-09 2008-10-14 Chemokine Therapeutics Corp. CXCR4 antagonist treatment of hematopoietic cells
US20060014682A1 (en) * 2000-05-09 2006-01-19 Chemokine Therapeutics Corporation CXCR4 antagonist treatment of hematopoietic cells
US6649189B2 (en) * 2000-06-26 2003-11-18 Rxkinetix, Inc. Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells
US20100222256A1 (en) * 2000-09-05 2010-09-02 Nobutaka Fujii Novel polypeptide anti-HIV agent containing the same
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7994114B2 (en) 2000-09-14 2011-08-09 British Canadian Biosciences Corp Chemokine mimetics synthesis and their use
US20070275892A9 (en) * 2000-09-14 2007-11-29 Chemokine Therapeutics Corp. Novel chemokine mimetics synthesis and their use
US20060252687A1 (en) * 2000-09-14 2006-11-09 Chemokine Therapeutics Corp. Novel chemokine mimetics synthesis and their use
US20060193826A1 (en) * 2001-07-31 2006-08-31 Anormed Inc. Methods to mobilize progenitor/stem cells
US7897590B2 (en) 2001-07-31 2011-03-01 Genzyme Corporation Methods to mobilize progenitor/stem cells
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US7935692B2 (en) 2001-07-31 2011-05-03 Genzyme Corporation Methods to mobilize progenitor/stem cells
US20060223180A1 (en) * 2001-07-31 2006-10-05 Anormed Inc. Methods to mobilize progenitor/stem cells
US20110129448A1 (en) * 2001-07-31 2011-06-02 Genzyme Corporation Methods to mobilize progenitor/stem cells
US20080063624A1 (en) * 2001-07-31 2008-03-13 Bridger Gary J Methods to mobilize progenitor/stem cells
US20050043367A1 (en) * 2001-07-31 2005-02-24 Gary Bridger Methods to mobilize progenitor/stem cells
US8410059B2 (en) 2002-08-27 2013-04-02 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
US20070066523A1 (en) * 2002-09-13 2007-03-22 Chemokine Therapeutics Corp. Chemokine analogs for the treatment of human diseases
US7091310B2 (en) 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
US20060275316A1 (en) * 2002-12-13 2006-12-07 Case Western Reserve University Modulation of cxcr4 and related methods and compositions
WO2005002522A2 (fr) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions et methodes pour traiter une ischemie tissulaire
WO2005002522A3 (fr) * 2003-06-30 2005-04-28 Caritas St Elizabeths Boston Compositions et methodes pour traiter une ischemie tissulaire
US20060194776A1 (en) * 2003-06-30 2006-08-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
WO2007036036A1 (fr) * 2005-09-29 2007-04-05 British Columbia Cancer Agency Branch Methode et composition pour moduler une greffage de cellules souches
US20090035318A1 (en) * 2005-09-29 2009-02-05 British Columbia Cancer Agency Branch Method and composition for increasing the engraftment efficiency of stem cells
EP2397148A2 (fr) 2006-02-02 2011-12-21 Allergan, Inc. Compositions et procédés pour le traitement d'une maladie ophtalmique
EP2407171A2 (fr) 2006-02-02 2012-01-18 Allergan, Inc. Compositions et procédés pour le traitement d'une maladie ophtalmique
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US8765683B2 (en) 2006-12-21 2014-07-01 Biokine Therapeutics Ltd. T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy
EP3011961A1 (fr) 2006-12-21 2016-04-27 Biokine Therapeutics LTD. 4F-benzoyl-TN14003 pour la mobilisation des cellules hématopoiétiques progénitrices en vue d'une transplantation
US20100184694A1 (en) * 2006-12-21 2010-07-22 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
US20100166715A1 (en) * 2006-12-21 2010-07-01 Amnon Peled T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
US8455450B2 (en) 2006-12-21 2013-06-04 Biokine Therapeutics Ltd. Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
US8663651B2 (en) 2006-12-21 2014-03-04 Biokine Therapeutics Ltd. T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
US20100143334A1 (en) * 2006-12-21 2010-06-10 Amnon Peled T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
EP2759302A2 (fr) 2006-12-21 2014-07-30 Biokine Therapeutics LTD. 4F-benzoyl-TN14003 combiné avec rituximab pour une utilisation dans le traitement d'une tumeure
KR20120037463A (ko) 2009-06-14 2012-04-19 바이오카인 테라퓨틱스 리미티드 혈소판 수준을 증가시키는 펩타이드 요법
CN102481332A (zh) * 2009-06-14 2012-05-30 拜欧肯疗法有限公司 用于提高血小板水平的肽疗法
WO2010146578A3 (fr) * 2009-06-14 2011-02-10 Biokine Therapeutics Ltd. Thérapie à base de peptides pour augmenter les niveaux de plaquettes
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
WO2012095849A1 (fr) 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides et compositions pour le traitement de tumeurs issues du neuroectoderme et de rétinoblastomes
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
WO2013160895A1 (fr) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides et leur utilisation dans le traitement du cancer du poumon à grandes cellules
WO2014155376A1 (fr) 2013-03-24 2014-10-02 Biokine Therapeutics Ltd. Méthodes de traitement de la leucémie myéloïde
WO2015063768A1 (fr) 2013-10-31 2015-05-07 Biokine Therapeutics Ltd. Méthodes de traitement de la leucémie myéloïde aiguë avec mutation de la flt3
WO2015114638A2 (fr) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Méthode d'élimination de cellules souches
US11612638B2 (en) 2015-07-16 2023-03-28 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11596666B2 (en) 2015-07-16 2023-03-07 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
US11648293B2 (en) 2015-07-16 2023-05-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11534478B2 (en) 2015-07-16 2022-12-27 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11554159B2 (en) 2015-07-16 2023-01-17 Blokine Therapeutics Ltd. Compositions and methods for treating cancer
US11559562B2 (en) 2015-07-16 2023-01-24 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11590200B2 (en) 2015-07-16 2023-02-28 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11642393B2 (en) 2015-07-16 2023-05-09 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11607444B2 (en) 2015-07-16 2023-03-21 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11638743B2 (en) 2015-07-16 2023-05-02 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US11638742B2 (en) 2015-07-16 2023-05-02 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10993985B2 (en) 2016-02-23 2021-05-04 BioLmeRx Ltd. Methods of treating acute myeloid leukemia
WO2019097514A1 (fr) 2017-11-14 2019-05-23 Yeda Research And Development Co. Ltd. Cellules souches hématopoïétiques présentant des propriétés améliorées
US11834678B2 (en) 2017-11-14 2023-12-05 Yeda Research And Development Co. Ltd. Hematopoietic stem cells with improved properties
WO2020065647A1 (fr) 2018-09-25 2020-04-02 Biolinerx Ltd. Procédés de sélection d'un traitement contre un cancer associé aux récepteurs cxcr4

Also Published As

Publication number Publication date
CA2305787A1 (fr) 2001-11-09
US20110118193A1 (en) 2011-05-19
US20110230422A1 (en) 2011-09-22
US20060014682A1 (en) 2006-01-19
US7435718B2 (en) 2008-10-14
US20090192082A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
AU2001258110B2 (en) Cxcr4 antagonist treatment of hematopoietic cells
US7435718B2 (en) CXCR4 antagonist treatment of hematopoietic cells
AU2001258110A1 (en) Cxcr4 antagonist treatment of hematopoietic cells
EP1061944B1 (fr) Antagonistes therapeutiques du recepteur de chemokine
US7354899B2 (en) Methods of treating autoimmune diseases comprising administering CXCR4 antagonists
AU2001252081B2 (en) Cxcr4 agonist treatment of hematopoietic cells
US7378098B2 (en) CXC chemokine receptor 4 agonist peptides
AU2001252081A1 (en) CXCR4 Agonist Treatment of Hematopoietic Cells
WO2000009152A1 (fr) Antagonistes therapeutiques du recepteur de la chimiokine
KR100222274B1 (ko) 결합되지 않은 mpl 수용체를 사용하여 혈소판 생산을 자극하기 위한 조성물 및 방법
AU2005201244B2 (en) CXCR4 agonist treatment of hematopoietic cells
CA2408319A1 (fr) Traitement de cellules hematopoietiques base sur des antagonistes du cxcr4
CA2405907A1 (fr) Traitement de cellules hematopoietiques utilisant des agonistes de cxcr4
CA2305036A1 (fr) Traitement de cellules hematopoietiques a l'aide d'agonistes du cxcr4
CA2322764A1 (fr) Antagonistes therapeutiques du recepteur de chemokine

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHEMOKINE THERAPEUTICS CORPORATION, BRITISH COLUMB

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TUDAN, CHRISTOPHER R.;MERZOUK, AHMED;ARAB, LAKHDAR;AND OTHERS;REEL/FRAME:012200/0122;SIGNING DATES FROM 20010622 TO 20010625

Owner name: UNIVERSITY OF BRITISH COLUMBIA, THE, BRITISH COLUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EAVES, CONNIE J.;CASHMAN, JOHANNE;CLARK-LEWIS, IAN;REEL/FRAME:012200/0136;SIGNING DATES FROM 20010621 TO 20010625

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION